Zacks Investment Research cut shares of Recordati (OTCMKTS:RCDTF) from a buy rating to a hold rating in a report published on Wednesday morning.
According to Zacks, “Recordati S.p.A. is a pharmaceutical company. It engaged in the research, development, manufacturing and marketing of pharmaceuticals for rare disease treatments. The company operates primarily in Russia, Turkey, North Africa and United States of America. Recordati S.p.A. is headquartered in Milan, Italy. “
RCDTF stock opened at $42.00 on Wednesday. Recordati has a fifty-two week low of $42.00 and a fifty-two week high of $42.00. The company has a market cap of $9,828.88, a price-to-earnings ratio of 30.66, a price-to-earnings-growth ratio of 2.93 and a beta of -0.38.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Recordati Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Recordati and related companies with MarketBeat.com's FREE daily email newsletter.